Clinical trials: Macular Neovascularisation
Maculopathy, Age-Related, Choroidal Neovascularization
Age-related Macular Degeneration: Detection of Onset of New Choroidal Neovascularization (AMD DOC Study)
The purpose of this study is to determine the sensitivity of the optical coherence tomography (OCT) test in detecting neovascular AMD in eyes at high risk for CNV development.
- Trial name
- NCT00417846
- Where
- 4 sites in United States
- Volunteers
- 98 people
- Sponsor
- Johns Hopkins University
Neovascular Age Related Macular Degeneration
A Study to Assess the Effects of Brolucizumab in Adult Patients With Neovascular Age Related Macular Degeneration
Neovascular age-related macular degeneration (nAMD) is characterized by the presence of choroidal neovascularization (CNV). Choroidal neovascularization consists of abnormal blood vessels originating from the choroid and can lead…
- Trial name
- OCTOPUS (NCT04239027)
- Testing
- RTH258/Brolucizumab
- Where
- 40 sites in France
- Volunteers
- 210 people
- Sponsor
- Novartis Pharmaceuticals
Age Related Macular Degeneration, Choroidal Neovascularization
Home Vision Monitoring Using the ForeseeHome Device Following Treatment of Neovascular Age Related Macular Degeneration
ForeseeHome, an FDA-approved home device, was specifically designed for unsupervised Preferential-Hyperacuity-Perimeter (PHP) testing of Age Related Macular Degeneration (AMD) patients at home by characterizing central and…
- Trial name
- CNV (NCT01334294)
- Testing
- ForeseeHome
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Notal Vision Ltd.
Age-related Macular Degeneration
Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Patients will receive injections of ranibizumab.
- Trial name
- MAKO (NCT02727881)
- Testing
- Squalamine lactate ophthalmic solution, 0.2%, ranibizumab
- Where
- 118 sites in United States
- Volunteers
- 230 people
- Sponsor
- Ohr Pharmaceutical Inc.
Macular Degeneration, Choroidal Neovascularization
Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD)
This study will evaluate the effect of combination therapy with verteporfin photodynamic therapy and ranibizumab on visual acuity compared to ranibizumab monotherapy and the durability of response observed in patients with…
- Trial name
- NCT00433017
- Testing
- Verteporfin Photodynamic Therapy, Ranibizumab
- Where
- 12 sites in Austria, Belgium and 10 more
- Volunteers
- 255 people
- Sponsor
- Novartis
Neovascular Age Related Macular Degeneration(nAMD)
A Study to Evaluate the Efficacy and Safety of VIS-101 in Participants With Neovascular Age-Related Macular Degeneration
This study will evaluate the efficacy, safety, durability, and pharmacokinetics of VIS-101 administered at intervals as specified in the protocol, compared with aflibercept once every 8 weeks (Q8W), in participants with…
- Trial name
- ASCEND (NCT07798375)
- Testing
- VIS-101 6.0mg Low concentration, VIS-101 6.0mg High concentration, VIS-101 9.0mg High concentration
- Volunteers
- 244 people
- Sponsor
- Everest Medicines (China) Co.,Ltd.
Macular Neovascularization Secondary to Age-Related Macular Degeneration
4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Trial name
- NCT06864988
- Testing
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Where
- 94 sites in United States, Canada
- Volunteers
- 480 people
- Sponsor
- 4D Molecular Therapeutics
Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion
Impact of Lucentis on Psychological Morbidity in Patients With Retinal Vein Occlusion
This is a prospective, single-center, non-randomized clinical study on the impact of intravitreally administered ranibizumab (Lucentis) treatment on vision-related functioning and emotional well-being in subjects with central or…
- Conditions
- Venous Retinal Branch Occlusion, Central Retinal Vein Occlusion, Retinal Vein Occlusion, Depression
- Trial name
- NCT01011374
- Testing
- ranibizumab (Lucentis)
- Where
- United States
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Retina Associates of Cleveland, Inc
Age - Related Macular Degeneration (AMD), Diabetic Macular Edema
Wide Field OCTA in Ocular Diseases
The main retinal diseases, whether or not associated with specific mutations genetic, cause progressive degeneration of vascular retinal structures and not vascular, resulting in decreased visual function.
- Conditions
- Age - Related Macular Degeneration (AMD), Diabetic Macular Edema, Diabetic Retinopathy, Myopia
- Trial name
- WOOD-2025 (NCT07298174)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Age Related Macular Degeneration, Choroidal Neovascularization
SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
Ranibizumab is a humanised recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A.
- Trial name
- NCT00331864
- Testing
- Ranibizumab
- Where
- Switzerland
- Volunteers
- 531 people
- Sponsor
- Novartis
Age Related Macular Degeneration
Correlation Between Visual Field Defects on FORESEE HOME and on Optical Coherence Tomography in Choroidal Neovascularization Subjects
The FORESEE HOME is used in the recent years to detect Age-related Macular Degeneration (AMD) lesions. The device is capable of differentiation as to stages of AMD and early detection of changes including choroidal…
- Trial name
- NCT00884637
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- Notal Vision Ltd.
Choroidal NeoVascularization, Age-Related Macular Degeneration
Does Vascular Endothelial Growth Factor (VEGF) or Complement Factor H Gene Polymorphism Play a Role in the Treatment Success With VEGF Inhibitors in Patients With Choroidal NeoVascularization (CNV)?
Age related macular degeneration (AMD) is a multifactorial disease with a strong genetic component. Most importantly a genetic polymorphism in the gene encoding for the complement factor H (CFH) has been recently identified which…
- Trial name
- NCT00813514
- Testing
- VEGF genotyping
- Where
- Austria
- Sponsor
- Medical University of Vienna
Wet Macular Degeneration, Wet Age-related Macular Degeneration
Ziv-aflibercept Efficacy in Better Regulating AMD
This is a randomized, open-label, interventional, controlled study to determine the effects of Zaltrap on Neovascularized Wet Macular Degeneration as compared to the control anti-vascular endothelial growth factor ("anti-VEGF")…
- Trial name
- ZEBRA (NCT03423823)
- Testing
- Ziv-Aflibercept 25 MG/ML [Zaltrap], Ranibizumab
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Kapil Kapoor
Age Related Macular Degeneration
PreView PHP Preferential Hyperacuity Perimeter for the Detection of Choroidal Neovascularization
The primary objective of this study is to assess the ability of the PreView PHP(study device)to detect newly diagnosed non-treated Choroidal Neovascularization (CNV)lesion associate with advanced Age-related Macular Degeneration…
- Trial name
- NCT00358345
- Where
- Israel
- Volunteers
- 347 people
- Sponsor
- Notal Vision Ltd.
Macular Degeneration, Choroidal Neovascularization
A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib
To evaluate the safety and efficacy of the combination treatments in wet age-related macular degeneration. The combination treatment consists of verteporfin photodynamic therapy and either triamcinolone acetonide or pegaptanib…
- Trial name
- VERITAS (NCT00242580)
- Testing
- Verteporfin photodynamic therapy, Pegaptanib, Triamcinolone acetonide
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Novartis Pharmaceuticals
Neovascular Age-Related Macular Degeneration
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and efficacy of single and repeated intravitreal injections of GB-102 in subjects with neovascular (wet) age-related macular degeneration.
- Trial name
- NCT03249740
- Testing
- GB-102, Aflibercept
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Graybug Vision
Choroidal Neovascularization, Macular Degeneration
Macular Photocoagulation Study (MPS)
To evaluate laser treatment of choroidal neovascularization (CNV) through randomized, controlled clinical trials. The Macular Photocoagulation Study (MPS) consisted of three sets of randomized, controlled clinical trials.
- Conditions
- Choroidal Neovascularization, Macular Degeneration, Histoplasmosis
- Trial name
- NCT00000158
- Testing
- Argon Blue-Green Laser Photocoagulation
- Sponsor
- National Eye Institute (NEI)
Macular Degeneration
Clinical Study Of EYE001 For Wet-Type AMD (Age-Related Macular Degeneration)
This study will examine the efficacy and safety of pegaptanib sodium in Japanese patients with wet-type AMD, in order to establish that there is no large difference in the efficacy and the safety of the drug between Western and…
- Trial name
- NCT00150202
- Testing
- pegaptanib sodium
- Where
- 14 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Pfizer
Macular Degeneration
A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration
A study evaluating Retisert in patients with age-related macular degeneration
- Trial name
- NCT00032396
- Testing
- Retisert Implant
- Where
- United States
- Sponsor
- Control Delivery Systems
Age Related Macular Degeneration
Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results
This is an open label study to evaluate 2.0 mg intravitreal aflibercept injection administered in subject who have active choroidal neovascularization due to Age Related Macular Degeneration (AMD).
- Trial name
- NCT01657669
- Testing
- Intravitreal Aflibercept injection
- Where
- 3 sites in United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Retina Research Institute, LLC